Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sacrosidase
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sucraid® Offers Free 4-Day Trial, Only FDA-Approved CSID Therapy
Details : Sucraid (sacrosidase) oral solution is indicated for treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency, in adult & pediatric patients 5 months of age & older.
Product Name : Sucraid
Product Type : Enzyme
Upfront Cash : Inapplicable
March 01, 2025
Lead Product(s) : Sacrosidase
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacrosidase
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
Product Name : Sucraid
Product Type : Enzyme
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : Sacrosidase
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacrosidase
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Optum Frontier Therapies
Deal Size : Undisclosed
Deal Type : Partnership
Details : Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).
Product Name : Sucraid
Product Type : Enzyme
Upfront Cash : Undisclosed
April 15, 2022
Lead Product(s) : Sacrosidase
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Optum Frontier Therapies
Deal Size : Undisclosed
Deal Type : Partnership